Neoadjuvant Tyrosine Kinase Inhibitors (TKI) Enables Surgery for Previously Unresectable 15 cm Anaplastic Thyroid Cancer Case Report: Neoadjuvant TKI for Thyroid Cancer

Deandra Kuruppu; Miassa Aljiboree; Julie Nguyen; Mira Milas; Christian Nasr; Jiaxin Niu; Thomas D. Shellenberger

doi:10.1016/j.aed.2026.03.005

March 1, 2026AACE Endocrinology and DiabetesOpen Access

Neoadjuvant Tyrosine Kinase Inhibitors (TKI) Enables Surgery for Previously Unresectable 15 cm Anaplastic Thyroid Cancer Case Report: Neoadjuvant TKI for Thyroid Cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the effectiveness of neoadjuvant BRAF and MEK inhibitors in converting unresectable anaplastic thyroid cancer to a resectable state.
Case report of a 63-year-old man with unresectable anaplastic thyroid cancer.
Initial treatment with cytotoxic chemotherapy and immunotherapy while awaiting molecular testing.
Transition to neoadjuvant dabrafenib and trametinib after identifying BRAF V600E mutation via next-generation sequencing.
Assessment of tumor size and surgical outcomes post-treatment.
Significant tumor regression from 15 cm to 5 cm after five months of TKI therapy.
Successful thyroidectomy and lymph node dissection achieved following treatment.
Complications included cardiomyopathy and subsequent metastasis.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Case report demonstrates that neoadjuvant TKI improves resectability in a BRAF V600E-mutated thyroid cancer patient, suggesting new treatment pathways.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kuruppu et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e865a333a821460cf74 https://doi.org/10.1016/j.aed.2026.03.005

View Full Paper

Ask AI

Bookmark

Share

Neoadjuvant Tyrosine Kinase Inhibitors (TKI) Enables Surgery for Previously Unresectable 15 cm Anaplastic Thyroid Cancer Case Report: Neoadjuvant TKI for Thyroid Cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Neoadjuvant Tyrosine Kinase Inhibitors (TKI) Enables Surgery for Previously Unresectable 15 cm Anaplastic Thyroid Cancer Case Report: Neoadjuvant TKI for Thyroid Cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading